Pfizer Profit Jumps In Q311

BMI View: Pfizer's decision to shed its nutrition and animal health businesses will be welcomed by investors, who are displaying preferences for pure-play pharmaceutical companies. The company is well positioned for medium-term growth, primarily due its strong late-stage pipeline, which includes Eliquis (apixaban) for stroke prevention, tofacitinib in rheumatoid arthritis and axitinib for kidney cancer. A key short-term risk to its outlook is failure to sustain the Lipitor (atorvastatin) franchise after the loss of US exclusivity on November 30

To read the full article, please choose one of the following options: